论文部分内容阅读
目的:评价熊去氧胆酸与门冬氨酸钾镁联用治疗急性病毒性肝炎患者的早期临床疗效。方法:选取2011年1月—2015年12月间确诊的急性病毒性肝炎患者99例,按照入院先后顺序将其分为对照组54例和观察组55例;对照组患者给予门冬氨酸钾镁注射液治疗,观察组患者在对照组治疗基础上加用熊去氧胆酸片治疗,评价两组患者治疗后的总痊愈率和肝功能各指标的变化情况。结果:两组患者治疗后的TBIL、AST、ALT各指标低于治疗前(P<0.05),痊愈率明显高于对照组(P<0.05)。结论:采用熊去氧胆酸与门冬氨酸钾镁联用治疗急性病毒性肝炎患者的早期疗效优于熊去氧胆酸。
OBJECTIVE: To evaluate the early clinical efficacy of ursodeoxycholic acid combined with potassium and magnesium aspartate in the treatment of patients with acute viral hepatitis. Methods: Ninety-nine patients with acute viral hepatitis diagnosed between January 2011 and December 2015 were selected and divided into control group (n = 54) and observation group (n = 55) according to the order of admission. Patients in the control group were given potassium aspartate Magnesium injection treatment, observation group patients in the control group based on the addition of ursodeoxycholic acid tablets treatment, evaluation of the two groups of patients after treatment, the total cure rate and changes in liver function indicators. Results: The indexes of TBIL, AST and ALT after treatment in both groups were lower than those before treatment (P <0.05), and the cure rate was significantly higher than that of the control group (P <0.05). CONCLUSION: Ursodeoxycholic acid combined with potassium and magnesium aspartate is superior to ursodeoxycholic acid in the treatment of acute viral hepatitis.